A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Seagen

Status and phase: Terminated; Phase 1

Conditions: Renal Cell Carcinoma

Treatments: Drug: everolimus; Drug: SGN-75

Study type: Interventional

Funder types: Industry

Identifiers

NCT01677390

SGN75-002

Details and patient eligibility

About

This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
• Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
• Measurable disease
• Eastern Cooperative Oncology Group performance status 0 or 1
• Adequate lung and renal function

Exclusion criteria

• Prior treatment with anti-CD70-directed therapy
• Received more than one prior treatment with an mTOR inhibitor

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

Arm 1

Experimental group

Description:

SGN-75, everolimus

Treatment:

Drug: SGN-75

Drug: everolimus